Usage, dosage and correct way of taking Mirikizumab

Mirikizumab is an IL-23 inhibitor developed by Eli Lilly. It is mainly used to treat inflammatory diseases caused by immune system abnormalities, especially in patients with moderate to severe ulcerative colitis (UC). Milizumab's mechanism of action reduces the excessive activation of immune cells by selectively inhibiting the function of IL-23, thereby alleviating disease symptoms. This article will focus on the usage, dosage and correct way of taking Milizumab to help patients better understand the use of this drug.

1. Basic principles of usage and dosage

Militizumab treatment is usually given as an injection, administered subcutaneously. The frequency and dosage of militizumab may vary based on individual patient circumstances. Recommended usage and dosage for patients with ulcerative colitis generally include the following:

Initial treatment phase: The recommended starting dose of milizumab is 150 mg each time, administered subcutaneously at 0, 4, and 8 weeks. This can help patients quickly control their condition and reduce the occurrence of inflammatory reactions.

Maintenance treatment phase: After the initial treatment phase, patients need to undergo maintenance treatment according to the doctor's recommendations. In general, the recommended dose for maintenance therapy is 150 mg injections every 12 weeks. In this way, it can help maintain patients' clinical remission status and reduce the risk of disease recurrence.

It should be noted that the specific dosage and frequency of militizumab should be adjusted based on the patient's clinical manifestations and treatment response. If a patient experiences adverse reactions or the drug is not working well, the doctor may consider adjusting the dose or changing the treatment plan. Therefore, patients should use militizumab under the guidance of professional doctors to ensure a personalized treatment plan.

2. How to take militizumab correctly

Militizumab is a subcutaneous injection. Patients need to pay attention to the following aspects when self-injecting at home:

Selection of injection site: The site of subcutaneous injection can be the abdomen or upper thigh area to avoid frequent injections in the same site. An area without obvious wounds or lumps should be chosen, and areas near joints or bony prominences should be avoided.

Injection steps: Before injection, the patient should ensure that the injection site is clean. It is recommended to wipe the skin with alcohol cotton balls. When opening the syringe of militizumab, care should be taken to maintain aseptic operation to avoid contamination of the drug. To inject, slowly insert the needle into the skin and then press the syringe to inject the medicine under the skin. After the injection, the needle should be pulled out of the skin and the injection site gently pressed with a sterile cotton ball.

Precautions: When self-injecting, patients should be careful to avoid infection at the injection site. If reactions such as redness, swelling, itching, etc. occur at the injection site, the patient should contact a doctor for evaluation in a timely manner. In addition, if patients encounter any questions or discomfort, they should communicate with their doctor or pharmacist in time to ensure the safety and effectiveness of treatment.

3. Monitoring and adjusting dosage

During the use of militizumab, patients need to undergo regular physical examinations and laboratory tests to monitor the treatment effect and rule out the occurrence of adverse reactions. Especially for immune system drugs, there may be immune-related adverse reactions, so regular check-ups are necessary to ensure the safety of treatment.

Patients need to maintain close communication with their doctors during treatment, especially when the condition is not effectively controlled or serious side effects occur. The doctor may adjust the dose or frequency of the medication based on the patient's condition. For example, if a patient experiences severe immune system-related adverse reactions, the drug may need to be temporarily discontinued or the dose reduced.

Milizumab, as an innovativeIL-23 inhibitor, has a significant effect in the treatment of moderate to severe ulcerative colitis. Correct usage and dosage are crucial to the therapeutic effect. Patients need to follow the doctor's instructions when using it, regularly monitor the efficacy, and make timely adjustments when side effects occur. With appropriate treatment, patients can effectively manage ulcerative colitis and improve their quality of life.

Reference materials:https://omvoh.lilly.com/